Jpmorgan Chase & CO Renalytix PLC Transaction History

Jpmorgan Chase & CO

  • $1.14 Trillion
  • Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Renalytix PLC stock. As of the latest transaction made, Jpmorgan Chase & CO holds 16,165 shares of RNLX stock, worth $2,424. This represents 0.0% of its overall portfolio holdings.

Number of Shares
16,165
Previous 41,996 61.51%
Holding current value
$2,424
Previous $36,000 91.67%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024
SELL
$0.23 - $0.93 $5,941 - $24,022
-25,831 Reduced 61.51%
16,165 $3,000
Q1 2024

May 10, 2024
SELL
$0.26 - $1.47 $1,646 - $9,309
-6,333 Reduced 13.1%
41,996 $36,000
Q4 2023

Feb 12, 2024
SELL
$0.33 - $1.61 $7,147 - $34,872
-21,660 Reduced 30.95%
48,329 $18,000
Q3 2023

Nov 14, 2023
SELL
$1.51 - $4.01 $7,752 - $20,587
-5,134 Reduced 6.83%
69,989 $111,000
Q2 2023

Aug 11, 2023
SELL
$2.0 - $2.92 $11,580 - $16,906
-5,790 Reduced 7.16%
75,123 $219,000
Q1 2023

May 11, 2023
SELL
$1.93 - $3.72 $2,422 - $4,668
-1,255 Reduced 1.53%
80,913 $195,000
Q4 2022

Feb 13, 2023
SELL
$1.06 - $2.21 $4,139 - $8,630
-3,905 Reduced 4.54%
82,168 $153,000
Q3 2022

Nov 14, 2022
SELL
$1.19 - $2.78 $2,781 - $6,496
-2,337 Reduced 2.64%
86,073 $110,000
Q2 2022

Aug 11, 2022
BUY
$2.45 - $7.81 $107,123 - $341,484
43,724 Added 97.85%
88,410 $218,000
Q1 2022

May 11, 2022
BUY
$5.88 - $15.9 $81,038 - $219,133
13,782 Added 44.6%
44,686 $309,000
Q4 2021

Feb 10, 2022
BUY
$13.43 - $27.4 $332,258 - $677,876
24,740 Added 401.36%
30,904 $492,000
Q3 2021

Nov 12, 2021
BUY
$17.91 - $34.78 $110,397 - $214,383
6,164 New
6,164 $124,000

Others Institutions Holding RNLX

# of Institutions
31
Shares Held
3.78M
Call Options Held
0
Put Options Held
0
View Full List

About Renalytix plc

RNLX Quotes by TradingView
  • Ticker RNLX
  • Exchange OTC
  • Sector Healthcare
  • Industry Health Information Services
  • Shares Outstandng 37,445,900
  • Market Cap $5.62M
  • Description
  • Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data ...
More about RNLX
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email